CoChat
Sign Up
Cited by 848Atherosclerosis and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.

Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

Fuster, V·1994·Circulation
DOI 10.1161/01.cir.90.4.2126
Open this paper in CoChat — free account

Abstract

Myocardial infarction is the most frequent cause of mortality in the United States as well as in most western countries. In this review, the processes leading to myocardial infarction are described based on the most recent studies of vascular biology; in addition, evolving strategies for prevention are outlined. The following was specifically discussed. (1) Five phases of the progression of coronary atherosclerosis (phases 1 to 5) and eight morphologically different lesions (types I, II, III, IV, Va, Vb, Vc, and VI) in the various phases are defined. (2) The present understanding of the pathogenesis of each of the phases of progression and of the various lesion types preceding myocardial infarction is described; particular emphasis is placed on the physical, structural, cellular, and chemical characteristics of the "vulnerable or unstable plaques" prone to disruption (types IV and Va lesions). (3) The fate of plaque disruption (type VI lesion) in the genesis of the various coronary syndromes and especially acute myocardial infarction is defined; particular emphasis is placed on the combination of plaque disruption and a high thrombogenic risk profile--local factors (ie, degree of plaque disruption, exposure of lipid-macrophage-rich plaque, etc) and systemic factors (ie, catecholamines, RAS, fibrinogen, etc)--in the genesis of myocardial infarction. (4) Strategies of regression or stabilization of "vulnerable or unstable plaques" for prevention of myocardial infarction are presented within the context of recent favorable experience with risk factor modification and lipid-modifying angiographic trials, beta-blockade and angiotensin-converting enzyme inhibition, antithrombotic strategies, and the possible role of estrogens. The recent past has been very fruitful in yielding a better understanding of the processes leading to myocardial infarction, and the near future appears very promising in terms of preventing the number 1 killer in the western world.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.cir.90.4.2126

Cites

240 of 240 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–240 of 240

Flagged first, then by citations

Cited by

Sorted by citations

See all 848

Related

See all

Metadata

Authors
Fuster, V
Affiliations
Mount Sinai Hospital (US)
Corresponding author
Fuster, V
ORCID
Fuster, V
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1994-10
Volume
90
Issue
4
Pages
2126-2146
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/01.cir.90.4.2126
OpenAlex
W2110185147
Cited by
848
References
240
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 4 · 2020: 14 · 2019: 6 · 2018: 5 · 2017: 12 · 2016: 19 · 2015: 16 · 2014: 19 · 2013: 24 · 2012: 18
FWCI
16.36
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
myocardial infarction, coronary artery disease, vulnerable plaque, plaque disruption, lesion type, plaque regression, thrombosis, coronary syndrome, risk factor control, lipid therapy, beta-adrenergic blockade, angiotensin-converting enzyme inhibition, antithrombotic therapy, estrogen, vascular biology
MeSH terms
Coronary Artery Disease, Coronary Thrombosis, Coronary Vessels, Humans, Myocardial Infarction, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review